These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 19847899

  • 1. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP, Italian Multiple Sclerosis Database Network (MSDN) Group.
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [Abstract] [Full Text] [Related]

  • 2. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [Abstract] [Full Text] [Related]

  • 3. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP, Italian Multiple Sclerosis Database Network Group.
    J Neurol Sci; 2009 Nov 15; 286(1-2):109-13. PubMed ID: 19615696
    [Abstract] [Full Text] [Related]

  • 4. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan 15; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study.
    Russo P, Paolillo A, Caprino L, Bastianello S, Bramanti P.
    J Eval Clin Pract; 2004 Nov 15; 10(4):511-8. PubMed ID: 15482413
    [Abstract] [Full Text] [Related]

  • 6. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K, Walsh C, Antonelli G, Hutchinson M.
    Mult Scler; 2007 Apr 15; 13(3):336-42. PubMed ID: 17439902
    [Abstract] [Full Text] [Related]

  • 7. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec 15; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 8. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.
    Neurology; 2007 Oct 09; 69(15):1498-507. PubMed ID: 17699802
    [Abstract] [Full Text] [Related]

  • 9. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 09; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 10. [Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients].
    Patrucco L, Rojas JI, Cristiano E.
    Rev Neurol; 2010 May 01; 50(9):529-32. PubMed ID: 20443171
    [Abstract] [Full Text] [Related]

  • 11. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 12. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P, Calabrese M, Biasi G, Gallo P.
    J Neurol; 2004 Mar 26; 251(3):305-9. PubMed ID: 15015010
    [Abstract] [Full Text] [Related]

  • 13. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 26; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 14. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct 26; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 15. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X.
    Ann Neurol; 2006 Feb 26; 59(2):344-52. PubMed ID: 16437558
    [Abstract] [Full Text] [Related]

  • 16. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 26; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 17. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X.
    Mult Scler; 2009 Jul 26; 15(7):848-53. PubMed ID: 19542263
    [Abstract] [Full Text] [Related]

  • 18. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
    Webb UH.
    J Neurosci Nurs; 2008 Dec 26; 40(6):356-61. PubMed ID: 19170303
    [Abstract] [Full Text] [Related]

  • 19. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
    Miller DM, Weinstock-Guttman B, Bourdette D, You X, Foulds P, Rudick RA.
    Mult Scler; 2011 Jun 26; 17(6):734-42. PubMed ID: 21300736
    [Abstract] [Full Text] [Related]

  • 20. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
    Trojano M, Paolicelli D, Zimatore GB, De Robertis F, Fuiani A, Di Monte E, Livrea P.
    Neurol Sci; 2005 Dec 26; 26 Suppl 4():S179-82. PubMed ID: 16388354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.